BCYC

Bicycle Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 3/10
  • Momentum↓ 2/10
Bicycle Therapeutics sales and earnings growth
BCYC Growth
Neutral
  • Revenue Y/Y↓ -23.20%
  • EPS Y/Y↓ -11.04%
  • FCF Y/Y↓ -18.83%
Bicycle Therapeutics gross and profit margin trends
BCYC Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -884.50%
  • ROIC↓ -763.20%
Bicycle Therapeutics net debt vs free cash flow
BCYC Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -1257.0

Bicycle Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗